Health Care Related Organization
Sage Therapeutics Files Lawsuit Against Biogen Following $469 Million Acquisition Offer
Sage Therapeutics, Biogen, lawsuit, acquisition offer, $469 million, neuroscience, pharmaceutical industry
Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security
Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.
Atara Biotherapeutics Faces Clinical Hold on EBVALLO and Pipeline Candidate Due to Manufacturing Site Inspection Issues
Atara Biotherapeutics, EBVALLO, Clinical Hold, FDA, Manufacturing Site Inspection, Cell Therapy, T-Cell Immunotherapy
Empowering Women’s Health: First Lady Jill Biden and Biopharma Leaders Unite at JPM25
JPM25, Women’s Health, First Lady Jill Biden, Biopharma, Healthcare Investment, J.P. Morgan Healthcare Conference
AstraZeneca Secures Full FDA Approval for Lymphoma Treatment Selected by CMS
AstraZeneca, FDA Approval, Lymphoma Treatment, CMS-Selected
Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs
Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.
AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma
AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval
Bayer Prepares for Critical Challenges Amid Xarelto Decline
Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25
FDA Rejects Atara’s Ebvallo Due to Manufacturing Issues, Not Efficacy or Safety Concerns
Atara Therapeutics, Ebvallo, FDA rejection, manufacturing issues, post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus (EBV), T-cell immunotherapy, Pierre Fabre Laboratories.
Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges
Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends